Laurent Servais
25 Papers
Laurent Servais is an academic researcher. The author has contributed to research in topics: Medicine & SMA*. The author has co-authored 11 publications.
Chat about Author
Papers
Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review
TL;DR: In this article , the authors conducted a systematic review of articles published up to January 2023 and found that the results of early treatment depend on the number of SMN2 copies and the initial neurological status of the patient.
Evolving regulatory perspectives on digital health technologies for medicinal product development
Seya Colloud,Thomas Metcalfe,Scott Askin,Shibeshih Belachew,Johannes Ammann,Timothy Kilchenmann,P. Strijbos,Damien Eggenspieler,Laurent Servais,C. Garay,Armin Ritzhaupt,Thorsten Vetter,Francesca Cerreta +12 more
TL;DR: In this article , a review of digital health technology tools (DHTTs) used in medicines development is presented, highlighting the need for increased collaboration between various stakeholders, including regulators (medicines regulators and device bodies), pharmaceutical sponsors, manufacturers of devices and software and academia.
First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD
Laurent Servais,Damien Eggenspieler,Margaux Poleur,Marc Grelet,F. Muntoni,Paul Strijbos,M. Annoussamy +6 more
TL;DR: The first-ever regulatory qualification of a digital variable, the stride velocity 95th centile (SV95C), as a primary endpoint by the European Medicines Agency (EMA), represents a landmark event that establishes the value of digital health technology and endpoints for drug approval.
19
Combination disease-modifying treatment in spinal muscular atrophy: A proposed classification.
Crystal M Proud,Eugenio Mercuri,Richard S. Finkel,Janbernd Kirschner,Darryl C. De Vivo,Francesco Muntoni,Kayoko Saito,Eduardo F Tizzano,Isabelle Desguerre,Susana Quijano-Roy,K. Benguerba,Dheeraj Raju,Eric Faulkner,Laurent Servais +13 more
TL;DR: This work validated a rational, systematic approach for defining/grouping survival motor neuron‐targeted disease‐modifying treatment (DMT) scenarios and forms the basis to explore the safety and efficacy profile of the different combinations of DMT in SMA.
15
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England
TL;DR: In this article , a cost-utility analysis using a combination of decision tree and Markov model structures was developed to estimate the lifetime health effects and costs of NBS for SMA, compared with no NBS, from the perspective of the National Health Service (NHS) in England.